Efficacy and Treatment Strategies in Advanced Cancers with Liver Metastasis Receiving Atezolizumab Therapy

References

• Barlesi F , Vansteenkiste J , Spigel D , et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, Phase 3 study. Lancet Oncol . 2018;19(11):1468–1479. doi:10.1016/S1470-2045(18)30673-9 30262187
   PubMed Web of Science ®Google Scholar
• Balar AV , Galsky MD , Rosenberg JE , et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, Phase 2 trial. Lancet . 2017;389(10064):67–76. doi:10.1016/S0140-6736(16)32455-2 27939400
   PubMed Web of Science ®Google Scholar
• Liu L , Bai X , Wang J , et al. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer. Clin Cancer Res . 2019;25(24):7413–7423. doi:10.1158/1078-0432.CCR-19-0558 31515453
   PubMed Web of Science ®Google Scholar
• Dong ZY , Zhong WZ , Zhang XC , et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res . 2017;23:3012–3024. doi:10.1158/1078-0432.CCR-16-2554 28039262
   PubMed Web of Science ®Google Scholar
• Hegde PS , Chen DS . Top 10 Challenges in Cancer Immunotherapy. Immunity . 2020;52:17–35. doi:10.1016/j.immuni.2019.12.011 31940268
   PubMed Web of Science ®Google Scholar
• Salmon H , Remark R , Gnjatic S , et al. Host tissue determinants of tumour immunity. Nat Rev Cancer . 2019;19:215–227. doi:10.1038/s41568-019-0125-9 30867580
   PubMed Web of Science ®Google Scholar
• Jenne CN , Kubes P . Immune surveillance by the liver. Nat Immunol . 2013;14(10):996–1006. doi:10.1038/ni.2691 24048121
   PubMed Web of Science ®Google Scholar
• Milette S , Sicklick JK , Lowy AM , et al. Molecular Pathways: targeting the Microenvironment of Liver Metastases. Clin Cancer Res . 2017;23:6390–6399. doi:10.1158/1078-0432.CCR-15-1636 28615370
   PubMed Web of Science ®Google Scholar
• Riihimäki M , Hemminki A , Fallah M , et al. Metastatic sites and survival in lung cancer. Lung Cancer . 2014;86(1):78–84. doi:10.1016/j.lungcan.2014.07.020 25130083
   PubMed Web of Science ®Google Scholar
• Hoang T , Dahlberg SE , Sandler AB , et al. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol . 2012;7:1361–1368. doi:10.1097/JTO.0b013e318260e106 22843087
   PubMed Web of Science ®Google Scholar
• Vokes EE , Ready N , Felip E , et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol . 2018;29(4):959–965. doi:10.1093/annonc/mdy041 29408986
   PubMed Web of Science ®Google Scholar
• McKay RR , Kroeger N , Xie W , et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol . 2014;65(3):577–584. doi:10.1016/j.eururo.2013.08.012 23962746
   PubMed Web of Science ®Google Scholar
• Zhou J , Peng H , Li K , et al. Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis. Immunity . 2019;50(2):403–417. doi:10.1016/j.immuni.2018.12.024 30709740
   PubMed Web of Science ®Google Scholar
• Brodt P . Role of the microenvironment in liver metastasis: from pre- to prometastatic niches. Clin Cancer Res . 2016;22(24):5971–5982. doi:10.1158/1078-0432.CCR-16-0460 27797969
   PubMed Web of Science ®Google Scholar
• Kato K , Cho BC , Takahashi M , et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol . 2019;20(11):1506–1517. doi:10.1016/S1470-2045(19)30626-6 31582355
   PubMed Web of Science ®Google Scholar
• Rini BI , Powles T , Atkins MB , et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet . 2019;393(10189):2404–2415. doi:10.1016/S0140-6736(19)30723-8 31079938
   PubMed Web of Science ®Google Scholar
• Schmid P , Rugo HS , Adams S , et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol . 2020;21(1):44–59. doi:10.1016/S1470-2045(19)30689-8 31786121
   PubMed Web of Science ®Google Scholar
• Crispe IN . Immune tolerance in liver disease. Hepatology . 2014;60(6):2109–2117. doi:10.1002/hep.27254 24913836
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L , Spira A , Ballinger M , et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet . 2016;387(10030):1837–1846. doi:10.1016/S0140-6736(16)00587-0 26970723
   PubMed Web of Science ®Google Scholar
• Rittmeyer A , Barlesi F , Waterkamp D , et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet . 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X 27979383
   PubMed Web of Science ®Google Scholar
• Rosenberg JE , Hoffman-Censits J , Powles T , et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet . 2016;387(10031):1909–1920. doi:10.1016/S0140-6736(16)00561-4 26952546
   PubMed Web of Science ®Google Scholar
• Davoli T , Uno H , Wooten EC , et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science . 2017;355(6322):355. doi:10.1126/science.aaf8399 28126774
   PubMed Web of Science ®Google Scholar
• Wang J , Sun H , Zeng Q , et al. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci Rep . 2019;9(1):13404. doi:10.1038/s41598-019-49771-0 31527697
   PubMed Web of Science ®Google Scholar
• Reck M , Mok TSK , Nishio M , et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med . 2019;7:387–401. doi:10.1016/S2213-2600(19)30084-0 30922878
   PubMed Web of Science ®Google Scholar
• West H , McCleod M , Hussein M , et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol . 2019;20:924–937. doi:10.1016/S1470-2045(19)30167-6 31122901
   PubMed Web of Science ®Google Scholar
• Crispe IN . The liver as a lymphoid organ. Annu Rev Immunol . 2009;27(1):147–163. doi:10.1146/annurev.immunol.021908.132629 19302037
   PubMed Web of Science ®Google Scholar
• Teng MW , Ngiow SF , Ribas A , et al. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res . 2015;75:2139–2145. doi:10.1158/0008-5472.CAN-15-0255 25977340
   PubMed Web of Science ®Google Scholar
• Gadgeel S , Rodríguez-Abreu D , Speranza G , et al. Updated Analysis From KEYNOTE-189: pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol . 2020;38:1505–1517. doi:10.1200/JCO.19.03136 32150489
   PubMed Web of Science ®Google Scholar
• Schaer DA , Geeganage S , Amaladas N , et al. The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy. Clin Cancer Res . 2019;25:7175–7188. doi:10.1158/1078-0432.CCR-19-0433 31409612
   PubMed Web of Science ®Google Scholar
• Tumeh PC , Hellmann MD , Hamid O , et al. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res . 2017;5(5):417–424. doi:10.1158/2326-6066.CIR-16-0325 28411193
   PubMed Web of Science ®Google Scholar
• Kodumudi KN , Woan K , Gilvary DL , et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res . 2010;16:4583–4594. doi:10.1158/1078-0432.CCR-10-0733 20702612
   PubMed Web of Science ®Google Scholar
• Demaria S , Volm MD , Shapiro RL , et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res . 2001;7:3025–3030.11595690
   PubMed Web of Science ®Google Scholar
• Jackaman C , Majewski D , Fox SA , et al. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo. Cancer Immunol Immunother . 2012;61:2343–2356. doi:10.1007/s00262-012-1307-4 22714286
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou V , Cobo M , Bordoni R , et al. IMpower132: PFS and Safety Results with 1L Atezolizumab plus Carboplatin/Cisplatin plus Pemetrexed in Stage IV Non-Squamous NSCLC. J Thorac Oncol . 2018;13:S332–S333. doi:10.1016/j.jtho.2018.08.262
   Web of Science ®Google Scholar